Literature DB >> 23034864

Prevalence and viral load of 51 genital human papillomavirus types and three subtypes.

Markus Schmitt1, Christophe Depuydt, Ina Benoy, Johannes Bogers, Jerome Antoine, Marc Arbyn, Michael Pawlita.   

Abstract

Of the 120 known human papillomaviruses (HPV), 51 HPV types infect the genital mucosa. Very little is known about the prevalence and viral load of the majority of these low-risk (Lr-) HPV types in screening populations. We determined the prevalence of 51 HPV types and three subtypes in 999 consecutive BD-SurePath™ liquid-based cervical cytology samples collected during routine gynecological health checks from Belgian women. This series of screening samples was enriched with ASC-US (n = 100), low-grade squamous intraepithelial lesion LSIL (n = 100) and high-grade squamous intraepithelial lesion (HSIL) (n = 97) and analyzed by BSGP5+/6+-PCR/MPG assay for 51 HPV types and three subtypes. In consecutive screening samples, any of the 54 genital HPV (sub)types was found in 37.1%; Hr-HPV types were detected more frequently (26.8%) than the 31 Lr-HPV types (16.4%) and the six possibly high-risk types (6.6%). High viral load infections were present in 17.0% of the screening population. Among the women with cytological abnormalities, the prevalence of high viral loads of Hr-HPV types increased from negative for intraepithelial lesion or malignancy (NIL/M) over ASC-US, LSIL to HSIL (5.3, 47.1, 84.2 and 91.8%, respectively). The prevalence of possibly Hr and Lr-HPV types increased from NIL/M to LSIL but declined to HSIL. From NIL/M to HSIL, Hr-HPV infections showed an increasing frequency of high viral loads compared to total DNA positivity, but the increase between LSIL and HSIL was small. Type-specific analyses revealed substantial differences between individual HPV types in these groups. Our study provides quantitative data for the whole spectrum of genital HPV in a Belgian screening population and in a representative set of women with cervical abnormalities.
Copyright © 2012 UICC.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23034864     DOI: 10.1002/ijc.27891

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  16 in total

1.  Evaluation and Optimization of the Clinical Accuracy of Hybribio's 14 High-Risk HPV with 16/18 Genotyping Assay within the VALGENT-3 Framework.

Authors:  Lan Xu; Anja Oštrbenk Valenčak; Mario Poljak; Marc Arbyn
Journal:  J Clin Microbiol       Date:  2020-05-26       Impact factor: 5.948

2.  Multiple human papillomavirus infections with high viral loads are associated with cervical lesions but do not differentiate grades of cervical abnormalities.

Authors:  Markus Schmitt; Christophe Depuydt; Ina Benoy; Johannes Bogers; Jerome Antoine; Marc Arbyn; Michael Pawlita
Journal:  J Clin Microbiol       Date:  2013-02-27       Impact factor: 5.948

3.  Clinical and Analytical Evaluation of the Anyplex II HPV HR Detection Assay within the VALGENT-3 Framework.

Authors:  Anja Oštrbenk; Lan Xu; Marc Arbyn; Mario Poljak
Journal:  J Clin Microbiol       Date:  2018-10-25       Impact factor: 5.948

4.  The distribution of high-risk human papillomaviruses is different in young and old patients with cervical cancer.

Authors:  Mariano Guardado-Estrada; Eligia Juárez-Torres; Edgar Román-Bassaure; Ingrid Medina-Martinez; Ana Alfaro; Rosa Elba Benuto; Michael Dean; Nicolás Villegas-Sepulveda; Jaime Berumen
Journal:  PLoS One       Date:  2014-10-08       Impact factor: 3.240

5.  Low prevalence of human papillomavirus in head and neck squamous cell carcinoma in the northwest region of the Philippines.

Authors:  Pia Marie Albano; Dana Holzinger; Christianne Salvador; Jose Orosa; Sheryl Racelis; Modesty Leaño; Danilo Sanchez; Lara Mae Angeles; Gordana Halec; Markus Schmitt; John Donnie Ramos; Michael Pawlita
Journal:  PLoS One       Date:  2017-02-15       Impact factor: 3.240

6.  Clinical and Analytical Performance of the Onclarity HPV Assay Using the VALGENT Framework.

Authors:  K Cuschieri; D T Geraets; C Moore; W Quint; E Duvall; M Arbyn
Journal:  J Clin Microbiol       Date:  2015-08-05       Impact factor: 5.948

7.  Biological evidence for a causal role of HPV16 in a small fraction of laryngeal squamous cell carcinoma.

Authors:  G Halec; D Holzinger; M Schmitt; C Flechtenmacher; G Dyckhoff; B Lloveras; D Höfler; F X Bosch; M Pawlita
Journal:  Br J Cancer       Date:  2013-06-18       Impact factor: 7.640

8.  Post-translational control of IL-1β via the human papillomavirus type 16 E6 oncoprotein: a novel mechanism of innate immune escape mediated by the E3-ubiquitin ligase E6-AP and p53.

Authors:  Martina Niebler; Xu Qian; Daniela Höfler; Vlada Kogosov; Jittranan Kaewprag; Andreas M Kaufmann; Regina Ly; Gerd Böhmer; Rainer Zawatzky; Frank Rösl; Bladimiro Rincon-Orozco
Journal:  PLoS Pathog       Date:  2013-08-01       Impact factor: 6.823

9.  Human papillomavirus type-specific prevalence in the cervical cancer screening population of Czech women.

Authors:  Ruth Tachezy; Jana Smahelova; Jana Kaspirkova; Martina Salakova
Journal:  PLoS One       Date:  2013-11-12       Impact factor: 3.240

10.  Evidence of the causal role of human papillomavirus type 58 in an oropharyngeal carcinoma.

Authors:  Lorena Baboci; Paolo Boscolo-Rizzo; Dana Holzinger; Roberta Bertorelle; Lorena Biasini; Angelika Michel; Markus Schmitt; Giacomo Spinato; Rossana Bussani; Laia Alemany; Giancarlo Tirelli; Maria Cristina Da Mosto; Annarosa Del Mistro; Michael Pawlita
Journal:  Virol J       Date:  2013-11-12       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.